October 2020

Cancerous diseases occur as a result of the excessive, uncontrolled growth of abnormal cells, which invade (grow into) and destroy other body tissues.

This makes its cell growth different from normal cell growth.

Instead of dying, these cells continue to grow and form new, abnormal cells. They develop in almost any organ or tissue of the body.

The origin of these changes is a result of damage to DNA.

DNA is in every cell and directs all its actions of which replication or growth is our major concern.

In a normal cell, when DNA gets damaged the cell either repairs the harm or the cell dies.

In this case, the damaged DNA is not repaired or its cell programmed to die. I

Instead, this cell goes on to make new cells that the body does not need, with the same damaged DNA as in the first cell.

In the United States and Canada, cancer is the second leading cause of death, next to heart disease.

Causes and risk factors

Usually, cancer develops gradually over many years, this is enhanced by a complex combination of environmental, nutritional, behavioral, and hereditary factors.

For reasons not well understood, the following factors stand to increase one’s chances of acquiring these malignant diseases.

Geographic region
Natural selection for hereditary
Age, especially people over the age of 50

For instance, it is has been discovered that more men than women develop cancer.

List of commonly formed cancers

1. Castleman disease
2. Malignancy of unknown primary
3. Breast cancer in men
4. Breast cancer in women
5. Brain and spinal cord tumor in children
6. Brain and spinal cord tumors in adults
7. Bone cancer
8. Bone metastasis
9. Colorectal cancer
10. Lungs (small cell type)
11. Lungs (non-small cell type)
12. Prostate cancer
13. Colorectal cancer
14. Bladder cancer
15. Ovarian cancer
16. Uterine cancer
17. Skin cancer
18. Kidney cancer
19. Leukemia cancer
20. Pancreatic cancer
21. Stomach cancer
22. Cervix cancer
23. Vaginal cancer
24. Vulva cancer
25. Penile cancer

Advances in Cancer Diagnosis and Treatment

A few years ago a cancer diagnosis carried little hope for survival because medical science had a poor understanding of the disease and how to control it.

Today about two-thirds of all Americans diagnosed with this condition live longer than five years.

While it is hard to claim that a patient with this condition is disease-free, long-term survival significantly improves if the patient has had no recurrence of it for five years after the initial diagnosis and treatment.

For years death rates from this disease were rising in developing countries.

The incidence of the disease has decreased because of public awareness, the decline in smoking, early detection, and new advances in medical therapy or management.

Leave a Reply

You must be logged in to post a comment.

Special Procedures

Click on Any Topic

Bone Marrow Transplants

Organ Transplants

Stem Cells



Physician Assisted Suicide

Medical Topics
  • Long-Term Data Back Anti-PD-1 in Advanced Non-Squamous NSCLC
    (MedPage Today) -- Long-term data from an early first-line trial of pembrolizumab (Keytruda) plus chemotherapy showed that more than half of patients with advanced non-squamous non-small cell lung cancer (NSCLC) remained alive at 3 years. In cohort...
  • Suze Orman's Schwannoma
    (MedPage Today) -- Financial advisor, author and former CNBC host Suze Orman has always stressed that it is a mistake for people to ignore their money problems. Now she wants you to know that "the most vital and stupid mistake I could ever make...
  • 'License' to Smoke After Negative Lung Screening?
    (MedPage Today) -- Some individuals appear to interpret a negative low-dose CT (LDCT) lung screening scan as a green light to resume smoking, a post hoc analysis of the National Lung Screening Trial (NLST) found. For example, highly nicotine dependent...
  • Hunting Resistance Mechanisms in RET-Fusion Lung Cancer
    (MedPage Today) -- As detected by circulating tumor DNA (ctDNA), acquired resistance to pralsetinib (Gavreto) in RET fusion-positive lung cancer was relatively uncommon, findings from the ARROW study suggested. In 42 non-small cell lung cancer...
  • Dual Checkpoint Blockade With Some Chemo Boosts OS in NSCLC
    (MedPage Today) -- A first-line immune checkpoint inhibitor combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) improved survival in patients with advanced non-small cell lung cancer (NSCLC) when added to a limited course of chemotherapy...
Content Protected Using Blog Protector By: PcDrome.